Progress on the development of therapeutics against West Nile virus

被引：71

作者：

Diamond, Michael S. ^{[1
,2
,3
,4
]}

机构：

[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA

[3] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA

[4] Washington Univ, Sch Med, Dept Immunol, St Louis, MO USA

来源：

ANTIVIRAL RESEARCH | 2009年 / 83卷 / 03期

关键词：

Therapy; West Nile virus; Antiviral; Antibody; Pathogenesis; JAPANESE ENCEPHALITIS-VIRUS; YELLOW-FEVER VIRUS; CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTOR-3; CD8(+) T-CELLS; ANTIBODY-DEPENDENT ENHANCEMENT; INTERFERON REGULATORY FACTOR-3; ORGAN TRANSPLANT RECIPIENTS; NONSTRUCTURAL PROTEIN NS1; ACUTE FLACCID PARALYSIS;

D O I：

10.1016/j.antiviral.2009.05.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

A decade has passed since the appearance of West Nile virus (WNV) in humans in the Western Hemisphere in New York City. During this interval, WNV spread inexorably throughout North and South America and caused millions of infections ranging from a sub-clinical illness, to a self-limiting febrile syndrome or lethal neuroinvasive disease. Its entry into the United States triggered intensive research into the basic biology of WNV and the elements that comprise a protective host immune response. Although no therapy is currently approved for use in humans, several strategies are being pursued to develop effective prophylaxis and treatments. This review describes the current state of knowledge on epidemiology, clinical presentation, pathogenesis, and immunobiology of WNV infection, and highlights progress toward an effective therapy. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：214 / 227

页数：14

共 318 条

[1] Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type I infection [J].